Back

Vγ9Vδ2 T cells are potent inhibitors of SARS-CoV-2 replication and exert effector phenotypes in COVID-19 patients

Gay, L.; Rouviere, M.-S.; Mezouar, S.; Richaud, M.; Gorvel, L.; Foucher, E.; Madakamutil, L.; La Scola, B.; Menard, A.; Allardet-Servent, J.; Halfon, P.; Frohna, P.; Cano, C.; Mege, J.-L.; Olive, D.

2022-04-19 immunology
10.1101/2022.04.15.487518 bioRxiv
Show abstract

V{gamma}9V{delta}2 T cells play a key role in the innate immune response to viral infections, including SARS-CoV-1 and 2, and are activated through butyrophilin (BTN)-3A. Here, the objectives were to: 1) characterize the effects of SARS-CoV-2 infection on the number, phenotype, and activation of V{gamma}9V{delta}2 T cells in infected patients, and 2) assess the effects of in vitro SARS-CoV-2 infection on the expression of BTN3A and its impact on the activation and response of V{gamma}9V{delta}2 T cells to an anti-BTN3A antibody. Blood V{gamma}9V{delta}2 T cells decreased in clinically mild SARS-CoV-2 infections compared to healthy volunteers (HV). This decrease was maintained up to 28 days and in the recovery period. Terminally differentiated V{gamma}9V{delta}2 T cells tend to be enriched on the day of diagnosis, 28 days after and during the recovery period compared to HV. Furthermore, these cells showed cytotoxic and inflammatory activities as shown by TNF, IFN{gamma} and CD107a/b increase following anti-BTN3A activation. Moreover, BTN3A upregulation and V{gamma}9V{delta}2 T cell infiltration were observed in a lung biopsy from a fatal SARS-CoV-2 infection, as compared to HV. In vitro, SARS-CoV-2 infection significantly increased BTN3A expression in macrophages and lung cell lines. The activation via BTN3A enhanced the anti-SARS-CoV-2 V{gamma}9V{delta}2 T cells cytotoxicity and IFN-{gamma} and TNF in SARS-CoV-2 infected patient. Increasing concentrations of anti-BTN3A were accompanied by an inhibition of viral replication. Altogether, these data suggest that V{gamma}9V{delta}2 T cells are important in the immune response against SARS-CoV-2 infection and that activation by an anti-BTN3A antibody may enhance their response. KEY POINTSO_LISARS-CoV-2 mediates upregulation of the key receptor of V{gamma}9V{delta}2 T cells BTN3A on lung tissues and cell lines as well as monocytes C_LIO_LIDuring SARS-CoV-2 infection, V{gamma}9V{delta}2 are differentiated and efficiently degranulate and secrete cytokines upon activation with BTN3A mAb C_LI

Matching journals

The top 3 journals account for 50% of the predicted probability mass.

1
Frontiers in Immunology
586 papers in training set
Top 0.1%
37.9%
2
Viruses
318 papers in training set
Top 0.4%
10.1%
3
PLOS ONE
4510 papers in training set
Top 34%
4.3%
50% of probability mass above
4
Journal of Virology
456 papers in training set
Top 1%
3.6%
5
Immunology
29 papers in training set
Top 0.2%
2.7%
6
Molecular Immunology
14 papers in training set
Top 0.1%
2.6%
7
PLOS Pathogens
721 papers in training set
Top 5%
2.1%
8
iScience
1063 papers in training set
Top 12%
1.9%
9
Frontiers in Physiology
93 papers in training set
Top 3%
1.7%
10
Journal of Medical Virology
137 papers in training set
Top 2%
1.7%
11
Scientific Reports
3102 papers in training set
Top 59%
1.7%
12
European Journal of Immunology
57 papers in training set
Top 0.3%
1.5%
13
The Journal of Immunology
146 papers in training set
Top 1%
1.3%
14
International Journal of Molecular Sciences
453 papers in training set
Top 10%
1.2%
15
The Journal of Infectious Diseases
182 papers in training set
Top 3%
1.2%
16
Virus Research
36 papers in training set
Top 0.8%
1.2%
17
ImmunoHorizons
21 papers in training set
Top 0.1%
1.2%
18
Clinical & Translational Immunology
22 papers in training set
Top 0.1%
1.2%
19
Frontiers in Pharmacology
100 papers in training set
Top 3%
1.2%
20
Virology
56 papers in training set
Top 0.5%
1.1%
21
Vaccines
196 papers in training set
Top 3%
0.7%
22
Cells
232 papers in training set
Top 6%
0.7%
23
Journal of Leukocyte Biology
40 papers in training set
Top 0.5%
0.7%
24
Microbiology Spectrum
435 papers in training set
Top 6%
0.6%
25
Allergy
23 papers in training set
Top 0.8%
0.6%
26
EBioMedicine
39 papers in training set
Top 1%
0.6%